In yeast and higher plants, separate genes encode the cytosolic and mitochondrial forms of glyoxalase II. In contrast, although glyoxalase II activity has been detected both in the cytosol and mitochondria of mammals, only a single gene encoding glyoxalase II has been identified. Previously it was thought that this gene (the hydroxyacylglutathione hydrolase gene), comprised 8 exons that are transcribed into mRNA and that the resulting mRNA species encoded a single cytosolic form of glyoxalase II. Here we show that this gene gives rise to two distinct mRNA species transcribed from 9 and 10 exons, respectively. The 9-exon-derived transcript encodes two protein species: mitochondrially targeted glyoxylase II, which is initiated from an AUG codon in a previously uncharacterized part of the mRNA sequence, and cytosolic glyoxalase II, which is initiated by internal ribosome entry at a downstream AUG codon. The transcript deriving from 10 exons has an in-frame termination codon between the two initiating AUG codons and hence only encodes the cytosolic form of the protein. Confocal fluorescence microscopy indicates that the mitochondrially targeted form of glyoxalase II is directed to the mitochondrial matrix. Analysis of glyoxalase II mRNA sequences from a number of species indicates that dual initiation from alternative AUG codons is conserved throughout vertebrates.
In yeast and higher plants, separate genes encode the cytosolic and mitochondrial forms of glyoxalase II. In contrast, although glyoxalase II activity has been detected both in the cytosol and mitochondria of mammals, only a single gene encoding glyoxalase II has been identified. Previously it was thought that this gene (the hydroxyacylglutathione hydrolase gene), comprised 8 exons that are transcribed into mRNA and that the resulting mRNA species encoded a single cytosolic form of glyoxalase II. Here we show that this gene gives rise to two distinct mRNA species transcribed from 9 and 10 exons, respectively. The 9-exon-derived transcript encodes two protein species: mitochondrially targeted glyoxylase II, which is initiated from an AUG codon in a previously uncharacterized part of the mRNA sequence, and cytosolic glyoxalase II, which is initiated by internal ribosome entry at a downstream AUG codon. The transcript deriving from 10 exons has an in-frame termination codon between the two initiating AUG codons and hence only encodes the cytosolic form of the protein. Confocal fluorescence microscopy indicates that the mitochondrially targeted form of glyoxalase II is directed to the mitochondrial matrix. Analysis of glyoxalase II mRNA sequences from a number of species indicates that dual initiation from alternative AUG codons is conserved throughout vertebrates.
In the cytosol the action of two glyoxalase enzymes together with reduced glutathione (GSH), collectively termed the glyoxalase system, is required to prevent the accumulation of methylglyoxal (MG), 1 a toxic by-product of glycolysis, amino acid, and ketone body metabolism (1, 2) , and hence to prevent accumulation of MG adducts (3) . MG spontaneously forms a hemithioacetal adduct with GSH. Glyoxalase I (lactoylglutathione lyase; EC 4.4.1.5) produces S-D-lactoylglutathione from this adduct (2) and glyoxalase II (hydroxyacylglutathione hydrolase; EC 3.1.2.6) in turn hydrolyzes S-D-lactoylglutathione to D-lactate and hence regenerates GSH (1) . Glyoxalase II is a member of the zinc metallohydrolase family having a ␤-lactamase fold (4) . It has broad substrate specificity for glutathione thiol esters, hydrolyzing a number of these species (besides S-D-lactoylglutathione) to their corresponding carboxylic acids and reduced glutathione. Among these substrates, 2-hydroxy thiol esters appear to be hydrolyzed with greatest efficiency (5) .
The glyoxalase system is ubiquitous throughout the eukaryotic and prokaryotic kingdoms (6) . In microorganisms it has been straightforward to demonstrate a function. For example, when Escherichia coli is grown on glycerol as the predominant carbon source, elevated MG levels are generated by the action of MG synthase on the metabolic intermediate, dihydroxyacetone phosphate. The glyoxalase system removes significant amounts of MG and has been shown to be critical for growth in this situation (7) . In yeast, one study reported a similar protective function during growth in glycerol-rich medium (8) , whereas another has reported that the enzyme system only protects significantly against exogenous MG (6) . In the latter study the contribution of glyoxalase I (encoded by a single gene GLX1) was demonstrated by gene knockout. Additional knockouts showed that two separately encoded isoforms of glyoxylase II, one cytosolic (GLO2) and one mitochondrial (GLO4), had a contributory role.
In addition to yeast, mitochondrial glyoxalase II activity has been detected in the tissues of higher eukaryotes including rat (9) and Arabidopsis thaliana (10) . The function of the mitochondrial pool of glyoxalase II activity is unknown. Of interest, glyoxalase I appears to be absent from mitochondria in the rat (9, 11) , however, S-D-lactoylglutathione has been detected in the mitochondria (12) and so may ultimately provide a substrate for glyoxalase II.
In higher plants, there is little information on glyoxalase I, but, as in yeast, distinct genes encoding cytosolic and mitochondrially expressed forms of glyoxalase II have been detected. Thus in A. thaliana five genes have been identified, three that appear to encode mitochondrial proteins (GLX2-1, GLX2-4, and GLX2-5), one that encodes a cytosolic protein (GLX2-2), and one whose function is currently uncharacterized (GLX2-3) (10, 13 ). An apparent homologue of one of the mitochondrial forms (AY054407 from Oryza sativa) has been overexpressed in tobacco and increases resistance to salinity (14) .
Interest in the mammalian glyoxalase system derives in part from evidence for the role of MG-derived advanced glycation end products in the pathogenesis of diabetic complications and other diseases (15) . A single gene encodes human glyoxalase I and its overexpression in bovine aortic endothelial cells has * The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
□ S The on-line version of this article (available at http://www.jbc.org) contains Supplementary Fig. 1 been reported to prevent MG accumulation and advanced glycation end product formation under hyperglycemic conditions (16) . In vertebrates there is a single gene encoding glyoxalase II, HAGH (hydroxyacylglutathione hydrolase) (5, 17, 18) .
The mRNA sequence of glyoxalase II identified by Mannervik and co-workers (5) contains eight coding exons that encode the 260-amino acid cytosolic form of the enzyme. In this paper, we demonstrate that extended transcripts from the human HAGH gene encode both cytosolic and mitochondrial isoforms of glyoxalase II, and that the previous mRNA sequence is incomplete. The cytosolic form originates by internal priming of protein synthesis from the initiating AUG codon previously identified in exon 1 (5) . The mitochondrial form arises from initiation of translation at an upstream AUG codon encoded on an upstream exon that can be fused in-frame to exon 1. Examination of GenBank TM nucleic acid sequences indicates that alternative translation initiation of HAGH transcripts is conserved throughout vertebrates giving a possible explanation for the production of vertebrate intramitochondrial glyoxalase II.
EXPERIMENTAL PROCEDURES
Determination of the 5Ј extent of the glyoxalase II mRNA and the production of constructs to test its function are described below. As the 5Ј end of the mRNA is very (G ϩ C) rich, 5% Me 2 SO (BDH) and 1 M betaine (Sigma) were included in all PCR to allow amplification. PCR amplification was performed using the Expand high fidelity system (Roche Diagnostics) except where a blunt end was produced with Pfu polymerase (Stratagene). All constructs were sequenced on an ABI310 automated sequencer (Applied Biosystems) using BigDye® Terminator version 3.1 sequencing reagents. All primers were synthesized by Invitrogen. All restriction endonuclease enzymes were purchased from New England Biolabs.
5Ј-RACE-RNA ligase-mediated RACE was performed using the GeneRacer kit (Invitrogen) as directed by manufacturer's instructions using total RNA extracted from HepG2 cells by the TRIzol method (Invitrogen). Thermoscript reverse transcriptase (Invitrogen) was used in the presence of 1.5 M betaine and 10% Me 2 SO. For priming of cDNA synthesis the primer 5Ј-GCAGCCTCCTTGGTCTCATCATCAATG-3Ј was used. Nested PCRs were performed using the primary primer 5Ј-GGCAGGCAGCACCTCTACCTTCAT-3Ј (primer 3, Fig. 1 ) in all cases. For secondary amplification the primer 5Ј-CGGTCAGGTTCTTC-CGCAAATCT-3Ј was used to amplify from exon 1 and the primer 5Ј-GCCGCGAGCCTCCGCCTCTTTTT-3Ј was used to amplify from the 5Ј end of exon A.
Reverse Transcriptase (RT)-PCR-Total RNA from HepG2 cells, HT1080 cells, and from human liver and kidney (Clontech total RNA panel) was used to synthesize poly(dT)-primed cDNA with Multiscribe reverse transcriptase (Applied Biosystems). Amplification across the exon A-exon 1 boundary was performed using the forward and reverse primers 5Ј-GGGCAGCTCGGCAGTCCAG-3Ј (forward, primer 1, Fig. 1 ) and 5Ј-GGCAGGCAGCACCTCTACCTTCAT-3Ј (reverse, primer 3, Fig.  1 ). Amplification of the coding exons was performed using the same forward primer with 5Ј-TCCCCAAATCCGCTGAAGGTG-3Ј (reverse, primer 4, Fig. 1) .
Plasmid Construction and Site-directed Mutagenesis-Constructs pPrA1-TOPO and pPrAB1-TOPO containing the promoter (Pr) and alternative 5Ј UTR sequences (A,1 or A,B,1) up to and including the exon 1 initiating ATG (ex1iATG) were made by ligation of two separate products. (i) Genomic sequence containing the core promoter region and exon A was amplified using 5Ј-ACGCAGACGATGTTCTTTCC-3Ј (forward) and 5Ј-CGGCAGCGCGGCCTTAG-3Ј (reverse) and subcloned into the pCR2.1 TOPO vector (Invitrogen) to give pPrA-TOPO. (ii) The cDNA sequence spanning exons A and 1 was amplified from HepG2 cDNA using primers 5Ј-GGGCAGCTCGGCAGTCCAG-3Ј (forward, primer 1, Fig. 1 ) and 5Ј-GGCAGGCAGCACCTCTACCTTCAT-3Ј (reverse, primer 3, Fig. 1 ). Two products were generated with and without exon B, and were subcloned into pCR2.1 TOPO to generate pA1-TOPO and pAB1-TOPO. (iii) Digestion of pPrA-TOPO at a vector HindIII and a unique StuI site 5 bases upstream of the 3Ј exon/intron boundary of exon A allowed replacement of the genomic sequence 3Ј of the StuI site with the cDNA sequence for both splice forms up to and including the Ex1iATG by ligating HindIII/StuI fragments excised from pA1-TOPO and pAB1-TOPO to yield constructs pPrA1-TOPO and pPrAB1-TOPO.
To generate a fusion of the glyoxalase II promoter and 5Ј UTR sequence with firefly luciferase, products were amplified from pPrA1-TOPO and pPrAB1-TOPO using M13 forward primer and 5Ј-GGCAG-GCAGCACCTCTACCTTCAT-3Ј (reverse) (primer 3, Fig. 1 ) and were digested with XbaI to give a compatible cohesive end. pGL3 basic vector (Promega) was first linearized by digestion with NcoI and then blunted by mung bean nuclease (New England Biolabs) removing the luciferase initiating ATG. Subsequently a cohesive vector end was generated with NheI to allow subcloning of the digested PCR products giving pPrA1-GL3 and pPrAB1-GL3, respectively. A positive control using the luciferase initiating ATG was generated as follows. The promoter and a shortened region of 5Ј UTR sequence (nucleotides Ϫ103 to ϩ263) not containing an initiating ATG was amplified from genomic DNA using 5Ј-ACGCAGACGATGTTCTTTCC-3Ј (forward) and 5Ј-GCGCTCAACT-TGTTTTGTCC-3Ј (reverse), and the product was subcloned into pCR2.1 TOPO vector to give pPrTOPO. The promoter sequence was subcloned into pGL3 basic after digestion with SacI and XhoI to give the positive control construct shown in Fig. 2 .
A negative control construct fused the same promoter sequence as in the positive control to firefly luciferase from which the initiating ATG had been deleted. pGL3 basic digested with NcoI and blunted as above was then digested with SacI and the glyoxalase II promoter insert was introduced as a SacI-EcoRV fragment.
ExA(iATG 3 TTG), ex1(iATG 3 TTG) mutants and exAϩ1(iATG 3 TTG) double mutants were generated from pPrA1-GL3 using the QuikChange TM site-directed mutagenesis kit (Stratagene). The phosphorylated oligonucleotides (with mismatched base emboldened) used were 5Ј-P-GCCCGGCCCGGGTCTTGGTGGTGGG-3Ј and 5Ј-P-CCG-TGGACGAGGGCACCTTGAAGGTAGAGG-3Ј.
To ensure a high level of luciferase expression for Western blotting, pCMV-A1-GL3 and pCMV-AB1-GL3 were derived from pPrA1-GL3 and pPrAB1-GL3. The glyoxalase II core promoter region was removed from these constructs by digestion with EcoRI and PvuII, an enzyme that cuts 2 bp downstream from the experimentally determined ϩ1 site (Fig.  1A) . This was replaced with the CMV immediate/early promoter sequence and a T7 promoter. First the CMV and Renilla luciferase region of pRL-CMV (Promega) were excised using BglII and XbaI and subcloned into pGEM3Zfϩ (Promega). This construct was digested with NheI, the 5Ј overhangs were filled with the Klenow fragment of DNA polymerase I (New England Biolabs). The appropriate fragment was excised with EcoRI digestion and the resulting fragment was ligated to digested pPrA1-GL3 and pPrAB1-GL3 constructs (above). Constructs pCMV-exAi(ATG 3 TTG) and pCMV-ex1i(ATG 3 TTG) were made using the same strategy.
Real Time PCR-Constructs pCMV-A1-GL3 and pCMV-AB1-GL3 were in vitro transcribed with T7 polymerase (Ambion) to yield 2-kb transcripts from each that spanned exons A and 1 or A,B and 1, respectively. Equal concentrations of each transcript determined by A 260 and agarose gel electrophoresis were mixed and used as a control for quantification by real time RT-PCR. HepG2 cell RNA and in vitro transcripts were used to synthesize cDNA with random hexamers.
Real time PCR were performed on an ABI PRISM 7700 sequence detection system with TaqMan 2ϫ Universal PCR mixture (Applied Biosystems). Primers and probes were designed to cross exon boundaries using the Primer Express program version 1.5 (Applied Biosystems, in each case) to specifically detect products deriving from mRNA and concentrations of each were optimized. For detecting exon A-exon 1 mRNA, primers 5Ј-CCGAGGCCTCGGTCCA-3Ј (forward) and 5Ј-GTCAGGTTCTTCCGCAAATCTG-3Ј (reverse) were used with probe 5Ј-6FAM-CCCTGCTGGGAGTTTTCTGCCACA-TAMRA-3Ј. For exon B-exon 1 mRNA, primer 5Ј-GCTGCCGGGCTCGAG-3Ј (forward) and 5Ј-GGCTGGACCTAGCGCTTTC-3Ј (reverse) were used with probe 5Ј-6-FAM-TGAGCGTGGCGCGGAGCG-TAMRA-3Ј.
Fluorescent Protein Constructs-The region encoding the mitochondrial targeting sequence of glyoxalase II was amplified with primers 5Ј-GGGCAGCTCGGCAGTCCAG-3Ј (forward, primer 1, Fig. 1 ) and 5Ј-GGTGCCCTCGTCCACGGTC-3Ј (reverse, primer 2, Fig. 1 ) using pPrA1-GL3 as template. The product was digested at an XmaI site three bases upstream of exAiATG. The pDsRed2-N1 vector (Clontech) was digested with AgeI, overhangs filled with the Klenow fragment of DNA polymerase I were then redigested with XmaI. Ligation yielded the vector pGII-DsRed2.
Luciferase Activity and Immunoblotting Assays-HepG2 cells (European Collection of Cell Cultures) were cultured in Eagle's modified essential medium (Sigma) supplemented with 10% fetal calf serum (First Link), 2 mM glutamine (Sigma), and 1% antibiotic/antimycotic solution (Sigma) in a humidified atmosphere containing 5% CO 2 . For luciferase assays cells were seeded at 4 ϫ 10 4 /well in 24-well plates, cultured for 24 h, and then transfected with 200 ng of firefly luciferase construct and 20 ng of pHRL-TK (Promega) per well using FuGENE 6 transfection reagent (Roche) according to manufacturer's instructions. Cells were lysed 48 h post-transfection in passive lysis buffer (Promega) and assayed using the dual luciferase assay system (Promega) according to manufacturer's instructions with a Mediators PhL luminometer.
For Western blotting cells were seeded at 3 ϫ 10 5 /well in 6-well plates cultured for 24 h and transfected with 1 g of each firefly luciferase construct per well using FuGENE 6. Whole extracts of transfected cells were prepared using SDS-PAGE loading buffer (19) heated to 100°C added directly to cells (150 l/well). The lysate was cleared by centrifugation (10,000 ϫ g, 10 min). Total protein was measured using the BCA assay system (Pierce) and samples were electrophoresed on an 8% polyacrylamide gel (19) and blotted to the polyvinylidene difluoride membrane (Pierce). Blots were blocked with 5% (w/v) nonfat milk powder in Tris-buffered saline at room temperature for 1 h. Goat anti-firefly luciferase primary antibody (Promega) was used at a 1:1000 dilution in blocking buffer for 1 h at room temperature. After washing with Trisbuffered saline containing 0.05% Tween 20, horseradish peroxidaseconjugated donkey anti-goat secondary antibody (Promega) was used for incubation at a dilution of 1:5000 at room temperature for 1 h. Antibody complexes were visualized by incubation with 3,3Ј,5,5Ј-tetramethylbenzidine (Calbiochem) for 30 min.
Confocal Microsocopy-HepG2 cells were seeded at 4 ϫ 10 4 /well on 13-mm/0.17-mm thick coverslips in 24-well plates. Cells were transfected with pGII-DsRed2 alone or were co-transfected with a carnitine palmitoyltransferase I-EGFP fusion construct (20) or with plasmid pEYFP-Mito (Clontech) (400 ng total DNA/well in each case). After 72 h cells were fixed for 30 min with 4% paraformaldeyde in Dulbecco's modified phosphate-buffered saline (Sigma), washed twice with saline (10 min each), and mounted using Vectashield Hard Set (Vector Laboratories). Cells were prepared for immunocytochemistry as described by Satoh et al. (21) using an anti-cytochrome c monoclonal antibody (6H2.B4, BD Pharmingen) and rabbit anti-mouse IgG1 fluorescein isothiocyanate conjugate (Dako). Images were obtained using a ϫ63 oil immersion objective of a Leica DMIRE2 confocal laser scanning microscope at 1024 ϫ 1024 pixel resolution using a pinhole diameter of 76 m and averaged 30 times. For cells transfected with multiple fluorescent proteins, signals were collected over a narrow wavelength band after excitation with one laser line at a time to exclude bleed through of signal from other fluorophores.
Bioinformatic Analysis-Details of the data base searches and alignment utilities are shown as Supplementary Materials.
RESULTS
Examination of Available HAGH mRNA Sequences-The first reported human cDNA sequence of HAGH (X90999) had 8 coding exons (5) . However, the NCBI Reference Sequence for HAGH mRNA (NM_005326) contains an additional 500-bp exon at the start of the sequence (termed exon A in this report). In the genomic sequence MapViewer (NCBI) shows that exon A is located some 3.7 kb upstream of the previously assigned first coding exon (exon 1, Ref. 5) and around 100 bp downstream of gene DKFZP566J2046. Examination of exon A shows the presence of an in-frame ATG (exAiATG) 144 bp upstream of the previously recognized initiation codon (ex1iATG) with no intervening stop codons. Initiation at exAiATG would add 48 extra amino acids to the amino terminus of glyoxalase II (Fig. 1A) . Examination of EST sequences (including CK824895 and BU176541) indicated a further class of transcript with a second novel exon (termed exon B) between exons A and 1. The presence of exon B introduces a stop codon in-frame with the upstream ATG in exon A thus preventing the addition of the amino-terminal sequence to glyoxalase II (Fig. 1B) .
5Ј Sequence Determination of HAGH mRNA-To confirm the presence of the two alternatively spliced HAGH transcripts, described above, and to determine the full-length 5Ј sequence, RNA ligase-mediated RACE of HepG2 RNA was performed with gene-specific primers located in exon 1. All products continued in a 5Ј direction past exAiATG and a proportion of the products contained exon B. The products were all truncated with respect to NM_005326.
To identify the transcription start site, primers were designed in exon A. Under optimized conditions, a single PCR product containing the 164-bp HAGH sequence was generated, and sequencing of 5 representative subclones identified a consistent 5Ј end of the mRNA sequence (shown as nucleotide 1, in Fig. 1A ). This cDNA sequence (AY576804) added an extra 33 bp of 5Ј mRNA sequence to that given in NM_005326 (Fig. 1A) , and these 33 bp agree in sequence with the corresponding segment of the genomic sequence of chromosome 16. RT-PCR using a forward primer in exon A and reverse primer in exon 1 showed that RNA from human liver, kidney, and HT1080 fibroblasts also contained both 5Ј splice variants in similar proportion to HepG2 (Fig. 1C) .
When RT-PCR was repeated with HepG2 and liver RNA using a forward primer in exon A and reverse primer in the 3Ј UTR sequence in exon 8 ( primers 1 and 4, Fig. 1A) 
Localization of Core Promoter Region-Examination of the genomic sequence at the 5Ј end of the HAGH gene shows that only 28 bp separate the experimentally determined ϩ1 site of HAGH from the single coding exon of gene DKFZP566J2046 (encoding a homologue of fumarylacetoacetate hydrolase) on the opposite DNA strand. Accordingly it appears likely that the core promoter of glyoxalase II resides in this small space between the two genes. A 1.1-kb genomic fragment containing this region (Ϫ839 to ϩ263, where ϩ1 is the first base of the mRNA sequence in Fig. 1 ) was subcloned into the pGL3 basic vector (Promega) and conferred promoter activity ϳ55-fold over background in transfected HepG2 cells (results not shown). Fragment-(Ϫ103 to ϩ263) showed comparable and possibly higher activity (95-fold over background). Whereas it cannot be assumed that all sequences relevant to physiological expression are contained within this region, fragment-(Ϫ103 to ϩ263) was included in constructs designed to examine the initiation of translation (described below).
Real Time PCR-To estimate the relative abundance of the A,1-8 and A,B,1-8 isoforms of the glyoxalase II mRNA in HepG2 cells, real time RT-PCR was carried out. Both cDNA synthesis and PCR amplification of the A,B,1-8 isoform may be intrinsically less efficient than of the A,1-8 isoform in view of the high G/C content of exon B (80%). To correct for this possibility, data from total cellular RNA were normalized to data obtained with a defined mixture of in vitro transcripts spanning exons A,B,1 and A,1 (i.e. covering the amplicon). Fig. 1C .
Nucleotide and Amino Acid Sequence Analysis of Glyoxalase II Orthologues-The mRNA sequences of a number of HAGH orthologues were examined to determine the extent of their conservation. All vertebrate sequences contained a highly conserved cytosolic coding region of 260 amino acids and all possessed an in-frame upstream ATG corresponding to human exAiATG, adding between 43 and 48 amino acids depending on the species. Using MitoProt analysis (22) the amino-terminal extension of all sequences except Gallus gallus was predicted to contain a mitochondrial targeting sequence with a score greater than 50% and all sequences were predicted to contain a cleavage site. Similar analysis of the glyoxalase II proteins without the amino-terminal extensions gave scores of less than 10% in all cases except for Bos taurus (37%), and none of the proteins contained a predicted cleavage site. These data are summarized in Table I .
Investigation of Translational Efficiency and ATG Usage in Both HAGH Splice Forms-To determine whether each splice form of human glyoxalase II mRNA could be translated efficiently, the core promoter region and 5Ј mRNA sequence for both splice forms up to and including the ex1iATG were fused in-frame to firefly luciferase that had had its own initiating ATG removed. In these constructs expression of luciferase should only arise by translation initiated from within the HAGH sequence. This was confirmed by a negative control made by fusing the same promoter sequence (i.e. lacking any initiating ATG from the HAGH sequence) to the firefly luciferase from which the initiating ATG had been deleted. A signal of Ͻ0.1% of positive control signal was obtained excluding the possibility that the functional protein could be produced by initiation from downstream ATG codons in the firefly luciferase gene. In contrast, constructs with either exons A and 1 or exons A, B, and 1 directed luciferase production at ϳ50 and 25% of the positive control value, respectively (Fig. 2) . These results suggest that internal initiation at ex1iATG can occur.
To determine the contribution of each ATG to translation initiation in the pPrA1-GL3 construct they were mutated singly and in combination to produce ExA(iATG 3 TTG), ex1(iATG 3 TTG), and exAϩex1 (iATG 3 TTG). Mutation of exAiATG reduced the luciferase signal by Ͻ10%, whereas mutation of ex1iATG reduced the signal by ϳ90% and mutation of both ATGs reduced the signal by 99% (Fig. 5) . Thus it appears that exAiATG is responsible for ϳ10% of initiation and ex1iATG is responsible for ϳ90%.
Immunoblotting of luciferase fusion proteins verified that initiation occurs at both exAiATG and ex1iATG and can occur from either ATGs in the A,1 transcript (Fig. 3) . Thus in the top row, two separate proteins are detected and the ratio of these proteins fits well with the relative expression apparent from the luciferase activity data (above). Addition of 48 amino acids to the amino-terminal of glyoxalase II would increase its size by 5 kDa, whereas an increase of 2-3 kDa is estimated. This may suggest cleavage within the mitochondrial targeting sequence, as predicted above.
Subcellular Targeting Conferred by the Amino-terminal Extension of Glyoxalase II-To determine whether the 48-residue extension of glyoxalase II initiating at ex1iATG affected subcellular targeting, this sequence was added in-frame to the amino terminus of the fluorescent protein DsRed2 and the fusion was expressed in HepG2 cells. pGII-DsRed2-transfected cells showed a punctate distribution of red fluorescence (Fig. 4,  A-C) , whereas a diffuse cytosolic distribution was seen with unmodified DsRed2 protein (not shown).
To determine whether the punctate distribution was because of mitochondrial targeting, HepG2 cells were co-transfected with pGII-DsRed2 and pEYFP-mito (Clontech), a plasmid that expresses a fusion of the mitochondrial matrix targeting sequence of cytochrome c oxidase subunit VIII linked to enhanced yellow fluorescent protein. The two signals appeared to be extensively co-localized (Fig. 4A) .
Previous studies suggested that a pool of glyoxalase II that is immunologically related to the cytosolic form is present in the intermembrane space (9, 11) , in contrast to the matrix distribution observed above. To determine whether the subcompartments of the mitochondria can be adequately resolved by confocal fluorescence microscopy, pGII-DsRed2 was co-expressed with GFP-tagged carnitine palmitoyltransferase I (CPT-EGFP), a fusion protein previously used as an outer membrane marker (20) . In other experiments, cells expressing pGIIDsRed2 were immunostained for cytochrome c, a marker previously used to visualize the intermembrane space (21) .
CPT-EGFP protein showed a reticular distribution (Fig. 4B) . Although the red and green signals did not co-localize, a significant proportion of the red signal was enclosed within the reticular structures bounded by green fluorescence (Fig. 4B) , which is consistent with matrix targeting by the glyoxalase II leader sequence.
Immunolabeling of cytochrome c also showed a reticular distribution. Permeabilization may have lead to poorer preservation of structure, but again the signal was distinct from that of the glyoxalase II leader-DsRed2 protein. Because both the inner and outer mitochondrial membranes give a reticular is present (shown in italics). In these transcripts the predicted open reading frame initiated by the upstream ATG (408) is terminated by the in-frame stop codon (ter) that is present in exon B. Initiation at the downstream ATG in exon 1 would give the same protein as from the A,1-8 splice form. C, cDNA was prepared using total RNA from (i) liver, (ii) kidney, (iii) HepG2 cells, and (iv) HT1080 cells, and PCR of glyoxalase II splice forms was performed using primers 1 and 3. The splicing of exon A to exon 1 results in a 200-bp product, and the presence of exon B between these exons results in a 296-bp product. All tissues show a similar pattern of splicing with the majority of transcripts appearing to lack exon B.
TABLE I
Analysis of amino-terminal extensions of the glyoxalase II protein in vertebrates mRNA sequences were obtained from GenBank™ as curated sequences, or were assembled from EST sequences and genomic clones (35) , and were then translated using ORFfinder (NCBI). Alignments were performed using the ClustalW program (36) . Full protein sequence alignments and the NCBI accession numbers of the clones considered are submitted as a supplementary figure (Fig. S1 ). Predicted sizes of ORF are shown and sequences of the amino-terminal extensions are aligned with the human sequences between the exon A and exon 1 Met residues. Asterisks indicate identical amino acids, colons indicate conserved substitutions, and dots indicate semiconserved substitutions. For the full-length proteins (Fig. S1) , MitoProt (22) strongly predicted mitochondrial targeting in mammals, and there was support for this in fish (Danio and Takifugu) and to a lesser extent in chicken. The predicted cleavage site position in each case is the residue number in the unspaced peptide sequence. Visual inspection of the nucleotide sequences surrounding the first ATG showed they conformed well to Kozak's consensus for initiation (34) in all mammalian species and in the chicken. The first ATGs were predicted to be in a poor context in fish, where the accepted consensus may not apply. 
DISCUSSION
In this report we have demonstrated the production of a novel mitochondrial isoform of glyoxalase II from HAGH transcripts, in addition to that of the previously characterized cytosolic isoform. The novel isoform results from initiation of translation at an in-frame ATG codon (exAiATG) in exon A. This is a previously uncharacterized exon upstream of exon 1, the exon that contains the previously described translation initiation site (ex1iATG) of glyoxalase II (5). The ability of the amino-terminal extension initiated at exAiATG to direct fluo- The left-hand panel shows the structures of reporter plasmids and the right-hand panel shows the activity of these constructs assessed by their ability to direct firefly luciferase expression in transfected HepG2 cells. Human glyoxalase II core promoter (Prom) sequence (Ϫ103 to ϩ1) and 5Ј mRNA sequences including exon A (exA) and exon 1 (ex1) up to and including ex1iATG, with or without exon B (exB) were fused in-frame to firefly luciferase (Fluc). In all constructs except the positive control, Fluc had its own initiatory ATG removed so that translational initiation was dependent on glyoxalase II sequence. The predicted initiating ATGs in the glyoxalase II sequence were removed singly and in combination by site-directed mutagenesis to examine their contribution to initiation of translation. In the negative control, there is no initiating ATG in either sequence. Firefly luciferase levels were measured in cells harvested after 48 h and were normalized for expression against co-transfected Renilla luciferase (phRL-TK vector). Data are expressed as the mean Ϯ S.D. of three independent experiments with three replicate wells in each case. The results show that initiation at either ATG can support translation. The ATG in exon 1 also supports translation in the presence of exon B.
FIG. 3. Immunoblotting of glyoxalase II-luciferase fusion proteins.
The left-hand panel shows the structures of reporter plasmids derived from the constructs in Fig. 2 but with a CMV promoter replacing the endogenous core promoter. The fusion conserved all but the first two bases of the glyoxalase II 5Ј UTR as determined in the present study (sequence AY576804). The right-hand panel shows luciferase protein expression in whole cell extracts of HepG2 cells that were transfected and harvested after 48 h and blotted using an anti-firefly luciferase antibody. An arrow indicates 61 kDa (the size of native luciferase). Where both initiating ATG codons are present providing two continuous reading frames (top row) two polypeptides are observed. Where exon B introduces an in-frame ter codon, only the shorter product is observed (second row). Removal of either initiating ATG in the transcript lacking exon B gives a single product of the expected size (third and forth rows). rescent protein to the mitochondrial matrix indicates that these 48 amino acids contain a mitochondrial targeting sequence. The conservation of this amino-terminal sequence in mammals, birds, and fish suggests a common mechanism for the production of vertebrate mitochondrial glyoxalase II.
We demonstrated in addition that there is a second splice form of the mRNA comprising exons A,B,1-8. Exon B introduces an in-frame termination codon between exAiATG and ex1iATG. This transcript was shown to produce only the cytosolic 260-amino acid form of glyoxalase II by initiation at ex1iATG. The A,B,1-8 transcript characterized here in human mRNA also has an equivalent in mouse mRNA, as judged by a reported EST (BY103863) and rat mRNA as present in the cDNA sequence described by Ji et al. (17) (U97667) . There is at present insufficient sequence deposited in data bases to determine whether exon B is present in other species.
The efficient translation of A,B,1-8 transcripts despite the presence of a 27-codon upstream open reading frame together with predominance of initiation at ex1iATG in A,1-8 transcripts, suggests that an internal ribosome entry site (IRES) may direct initiation at this codon. Preferential initiation at a downstream ATG can in some cases be observed when upstream ATG(s) are in poor context, but this is not the explanation because exAiATG is predicted to be in a good context (GTCATGG) according to Kozak's rules (23) , and is shown in our study to initiate translation. In contrast, the size and extensive secondary structure of the glyoxalase II predicted for the 5Ј UTR sequence (Fig. 5) is characteristic of mRNAs translated by internal ribosome entry (24) . Using the UTRscan program (25) (which predicts new IRES sequences on the basis of previously submitted IRES data) A,B,1-8 and A,1-8 were both predicted to contain an IRES (Fig. 5) . It needs to be borne in mind, however, that the small number of experimentally verified IRES sequences makes the prediction of new IRES uncertain (26) . In some instances generation of 5Ј cleaved or 5Ј truncated mRNA molecules have given false positives in in vitro tests for IRES activity (26) . This confounding explanation would not account for the presence of cytosolic glyoxalase II in cells because no shortened transcripts were detected by 5Ј RACE in this study. Attempts to confirm IRES function in glyoxalase II transcripts by in vitro translation gave very weak signals and in constructs containing both exAiATG and ex1iATG it was difficult to visualize products initiating at the upstream ATG. However, products initiating at ex1iATG were A and B) or with paraformaldehyde supplemented with 0.05% Triton X-100 (panel C) to permeabilize the cells for immunofluorescence. Cells were examined using confocal microscopy. The scale bars represent 5 m. A, co-transfection of the pGII-DsRed2 fusion construct with pEYFP-Mito (Clontech) indicated the co-localization of both proteins to the mitochondrial matrix. For clarity the EYFP has been false colored blue so that co-localization gives purple upon merging. Co-localization was apparent both at the default pinhole setting (not shown) and at a reduced pinhole setting chosen to maximize resolution as shown. B, HepG2 cells were co-transfected with the pGII-DsRed2 fusion construct and an outer mitochondrial membrane marker (CPT1-EGFP described in Ref. 20) . At default pinhole settings, partial colocalization of the signals was apparent (data not shown). Using smaller pinhole settings to maximize resolution indicated that the DsRed2 signal was distinct from the outer membrane but in certain fields was clearly bounded by it (see inset). C, HepG2 cells were transfected with the pGII-DsRed2 fusion construct and processed for immunofluorescence with a previously characterized antibody against cytochrome c (21), which faces the intermembrane space. Immune complexes were detected with a fluorescein isothiocyanate conjugate. A reticular distribution of cytochrome c was observed similar to other reports (21) . A punctate distribution of DsRed2 fluorescence was still observed as above but appeared weaker than in panels A or B presumably because of loss of protein upon permeabilization. Cytochrome c was apparent both in the transfected cell and in adjacent untransfected cells. The signals did not co-localize suggesting that the targeting sequence does not direct protein to the intermembrane space.
detected, consistent with IRES function (data not shown). In addition to the glyoxalase II mRNAs described here, other mRNAs have been described that utilize internal ribosome entry in combination with 5Ј cap-dependent initiation to generate alternative protein isoforms. For example, the Notch2 (27) and the PITSLRE protein kinase (28) mRNAs have been shown to contain an IRES within their coding region that directs the production of truncated isoforms with altered function. The requirement for separate A,1-8 and A,B,1-8 forms of the mRNA is currently not apparent. Speculatively the relative production of the two splice forms could be used to control the amount of cytosolic and mitochondrial enzymes, but further work will be required to establish if this is so.
Previous studies of rat liver mitochondria reported that multiple isoforms of glyoxalase II were present in the intermembrane space and matrix (9, 11) . Although the isoforms were similar in size, only glyoxalase II present in the intermembrane space was reported to react with an antiserum raised to the polymerized cytosolic enzyme, whereas matrix glyoxalase II was found to be antigenically distinct (11) , however, primary data was not shown. In contrast, we find that the mitochondrial targeting sequence present on glyoxalase II would give rise to a matrix form having 260 amino acids in common with the cytosolic form and so would be expected to be immunochemically similar. Within the resolution of our experiments we were unable to detect proteins targeted by this signal within the intermembrane space. The sequence and cleavage site of the amino-terminal pre-sequence predicted by MitoProt (22) are consistent with mitochondrial matrix targeting (29, 30) , and this agrees with the matrix distribution of mitochondrial glyoxalase II in yeast (6) .
The current study does not exclude the possibility of additional isoforms of mitochondrial glyoxalase II (as implied in the study of Talesa et al. (9, 11) ), which are not accounted for by alternative targeting of HAGH encoded proteins, but there is no clear evidence on this point. Although yeast and higher plants do have distinct mitochondrial glyoxalase II genes (37, 45) it is not clear that this is the case in vertebrates. Besides glyoxalase II, three other GenBank gene entries (MGC2605, MF-1, and HSCO) encode human proteins that contain the GloB domain (characteristic of zinc-dependent hydrolases, including glyoxylases) as predicted by the conserved domain data base (NCBI). Of these proteins only HSCO has been characterized, but it can be discounted because it has been shown to lack glyoxalase II activity (31) . MGC-2605 encodes proteins that are highly homologous to glyoxalase II but lack a predicted amino-terminal extension that would target them to mitochondria. MF-1 is encoded by alternative mRNA splice forms both of which appear to encode a mitochondrial targeting sequence. However, these isoforms are larger than proteins known to possess glyoxalase II activity, and in particular are longer than the mitochondrial isoforms of glyoxalase II reported by Talesa et al. (9, 11) .
In contrast, it may be that proteins encoded by the HAGH gene account for all mitochondrial glyoxalase II activity. We estimate that the ratio of transcripts A,1-8 to A,B,1-8 is ϳ1:2 in HepG2 cells. Furthermore, luciferase experiments suggest that initiation at exAiATG is ϳ12% as efficient as that at ex1iATG in A,1-8. Assuming similar stability of luciferase and glyoxalase II in the cytosol and mitochondria this would account for a steady state of ϳ95% cytosolic and 5% mitochondrial protein. Within the limits of the analysis, this compares reasonably with measurements of rat liver glyoxalase II activity where 85-90% was estimated to be cytosolic and 10 -15% mitochondrial (9, 11) . It therefore seems plausible that all vertebrate mitochondrial glyoxalase II will derive from the HAGH gene.
The precise role of vertebrate mitochondrial glyoxalase II still remains unclear. In plants and yeast both cytosolic and mitochondrial glyoxalase II play complementary roles in protection against the toxic effects of MG (6, 14) . It is possible that the mitochondrial enzyme hydrolyzes S-D-lactoylglutathione that has diffused or been transported into the mitochondrial matrix from the cytosol (12) . It has also been suggested that uptake of S-D-lactoylglutathione is a possible pathway for the mitochondrial import of GSH (12) , although direct import of GSH also occurs (32) . Alternatively mitochondrial glyoxalase II activity may be required to hydrolyze thiol esters of glutathione formed by non-enzymatic or enzymatic acyl transfer from mitochondrial thiol esters of coenzyme A (9) . For each of these putative functions, a matrix localization would seem appropriate. Defining the origin of a significant proportion of intramitochondrial glyoxalase II as we have done in this study will allow its functions to be defined, and also enable an evaluation of its possible role in disease processes.
